A Phase 2 interventional study of Tofimilast in Asthma, sponsored by Pfizer. Completed at 22 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-06-08.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
This is an initial proof of concept, phase to study to assess the safety and efficacy tofimilast for the chronic maintenance treatment of adults with persistent asthma
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 112 is above the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change from baseline in FEV1 compared to placebo
Change from baseline in other lung function parameters, disease control and quality of life compared to placebo
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer